ReviewPaediatric drugs2001
Ewing tumour: incidence, prognosis and treatment options.
Review in Paediatric drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 102 citations in OpenAlex.
- RNA-binding protein gene NOP58 exhibits crucial prognostic and therapeutic value in Ewing sarcoma.Hereditas · 2025Article
- Pediatric Axial Ewing Sarcoma: A Retrospective Population-Based Survival Analysis.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2024Article
- Review
- The development and external validation of a web-based nomogram for predicting overall survival with Ewing sarcoma in children.Journal of children's orthopaedics · 2024Article
- Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance.European journal of medical research · 2023Review
- Paratesticular Ewing's sarcoma.Radiology case reports · 2023Article
- Spectrum of anatomical variants, normal findings and pathology in and around the paediatric sternum.Pediatric radiology · 2022Article
- A Rare Presentation of Extraosseous Ewing Sarcoma Manifesting as a Dumbbell Tumor on the Nape of the Neck.Case reports in surgery · 2022Article
- Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma.Cancers · 2021Article
- [Round-cell sarcomas].Der Pathologe · 2019Review
- Human Pluripotent Stem Cell-Derived Neural Crest Cells for Tissue Regeneration and Disease Modeling.Frontiers in molecular neuroscience · 2019Review
- Ewing's sarcoma of the sternum necessitating complex resection and reconstruction.Case reports in plastic surgery & hand surgery · 2019Article
- The Histogenesis of Ewing Sarcoma.Cancer reports and reviews · 2017Article
- Article
- Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.American journal of nuclear medicine and molecular imaging · 2013Article
- Diversity of angiogenesis among malignant bone tumors.Molecular and clinical oncology · 2013Article
- Article
- Promiscuous partnerships in Ewing's sarcoma.Cancer genetics · 2011Review
- Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.Cancer imaging : the official publication of the International Cancer Imaging Society · 2009Review
- Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.Virchows Archiv : an international journal of pathology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ewing tumours, i.e. Ewing's sarcoma and malignant peripheral neuroectodermal tumours, are the second most common primary malignant tumours of bone in childhood and adolescence, with an annual incidence rate in Caucasians of 3 per 1 million children <15 years of age. Histopathologically small blue round cell tumours, Ewing tumours show a typical chromosomal rearrangement in >95% of cases linking the EWS gene on chromosome 22q12 to a member of the ETS transcription gene family, most commonly to Fli-1 on 11q24. This fusion contributes to the malignant potential of Ewing tumour cells, indeed antisense oligonucleotides may prevent tumour growth in vitro. After open biopsy, and histological and possibly molecular biological confirmation of the diagnosis, treatment consists of several months of multidrug cytostatic therapy and local therapy. Both surgery and radiotherapy may control local disease, but without consequent cytostatic chemotherapy all patients will eventually succumb to distant metastases. With the use of alkylating agents including doxorubicin, cyclophosphamide and/or ifosfamide, and other cytostatic drugs such as actinomycin D (dactinomycin), vincristine and etoposide, long-term survival can be achieved in >50% of patients with localised disease. Patients with clinically detectable metastases at diagnosis, patients not responding to therapy and patients with disease relapse have a significantly poorer prognosis. Maximum supportive care and local therapy managed by an experienced physician are required in all patients, and inclusion of high-risk patients in phase I and II studies is warranted. Hence, treatment of patients with Ewing tumours should be performed in experienced centres only and preferably within controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.